1. Introduction {#s0005}
===============

Migraine with aura is a complex brain disorder presenting clinically as attacks of transient neurological symptoms, mostly characteristic visual or somatosensory disturbances ([@b0070]). The symptoms are typically followed by head pain accompanied by photo- and phonophobia, i.e. the headache phase of the migraine attack. The pathophysiological mechanisms of this highly prevalent and disabling condition are not well understood. While the migraine aura symptoms *per se* are believed to be caused by a slowly propagating wave of gray matter depolarization, so called spreading depolarization (SD), it remains elusive why patients suffering from this disorder apparently are more susceptible to SD and the relation to the subsequent headache and associated symptoms is not clear ([@b0015]).

The thalamus is a nuclear complex located in the diencephalon between the midbrain and cortex. It has a critical role in relaying and modulating sensory information travelling from the periphery to the cortex. Recent data from pre-clinical and clinical studies suggest that the thalamus could play a key role in the disease mechanisms of migraine with and without aura ([@b0175]). More specifically, dysfunction of thalamocortical connections have been proposed to explain the increased sensitivity to pain and other sensory stimuli, as well as a reduced threshold for SD elicitation, in migraine ([@b0025], [@b0080]). The clinical features in migraine of photophobia ([@b0065], [@b0135]) and allodynia ([@b0005]) have also been suggested to depend on thalamic dysfunction. A multi-center MRI study investigating the volume of thalamic nuclei in 131 migraine patients (38 with aura) ([@b0125]) reported a reduced volume of several thalamic nuclei in patients compared to healthy controls, including the central nuclear complex, anterior nucleus and lateral dorsal nucleus. The authors suggested that the findings were indicative of abnormal processing of the affective and cognitive components of pain in migraine. The volume differences were not found when investigating the subgroups of migraine patients with and without aura specifically, possibly due to lack of statistical power. In contrast, another recent clinic-based study, using a different data analysis method, found increased volumes of the medial geniculate and anteroventral nuclei in migraine patients without aura compared to healthy controls ([@b0165]).

To investigate whether migraine with aura is associated with changes in thalamic volume, we analysed MRI data obtained from a large, cross-sectional population-based study which specifically included migraine patients with aura. We used two advanced, validated, complimentary analysis methods, i.e. both of the methods used in the two previous, abovementioned studies, to assess the volume of the thalamus and its nuclei. We sought to determine whether any of the previously reported abnormalities of thalamic nuclei volumes could be identified in a large sample of migraine patients with aura specifically.

2. Methods {#s0010}
==========

We based our analyses on data from the Women with Migraine with Aura Neuroimaging (WOMAN) study, which has previously been presented in detail ([@b0045], [@b0050]). In brief, we used the Danish Twin Registry ([@b0170]), to recruit female twins born 1931 to 1982, who based on earlier responses to a previously used questionnaire

[@b0055] were classified as screen positive for migraine with aura, co-twins to females screen positive to migraine with aura, or screen negative for migraine of any type. Women from these three groups were sent baseline questionnaires on health and lifestyle issues in waves in February 2011 to April 2014. Eligible questionnaire responders were telephone interviewed by physicians, who classified each participant's headaches according to the International Classification of Headache Disorders, 3rd edition beta version ([@b0075]). Twins with definite migraine with aura and their co-twins were invited to participate. Controls were selected among twin pairs where both twins reported no history of migraine (one twin randomly selected from each pair). Control twins were only included if their non-migraine status was confirmed at interview and if they had less than 30 days of tension-type headache in the preceding year. Detailed eligibility criteria have been presented previously ([@b0045]). Eligible subjects were invited to participate in the MRI part of the study at a single center in Copenhagen, Denmark. On average, patients were scanned 6 months and controls 4 months after completing the physician-conducted headache interview ([@b0045]). Detailed information regarding subject recruitment and participation are provided in a previous publication ([@b0045]). Importantly, analyses comparing participants and non-participants indicated no major selection biases. Subjects received no financial reward for participating. The study was approved by the Ethics Committee of the Region of Southern Denmark and the Danish Data Protection Agency. Written informed consent was obtained from all participants. The study is registered at clinicaltrials.gov (NCT02047695).

2.1. MRI acquisition {#s0015}
--------------------

All participants underwent whole-brain MRI using the same 3.0 T magnetic resonance scanner (Siemens Magnetom Verio, Erlangen, Germany) equipped with a 32-channel receive head coil. Structural imaging was based on a T1-multi-echo 3D FLASH sequence as part of a whole-brain quantitative MRI protocol ([@b0080]) with the following parameters: repetition time = 18.7 ms echo time = 2.20, 4.70, 7.20, 9.70, 12.20 and 14.70 ms, flip, angle 20 degrees, field of view = 256 mm, 176 sagittal slices. In-plane acquisition was accelerated by 2-fold using generalized autocalibrating partially parallel acquisitions ([@b0065]) with 18 reference lines. Prior to further processing, images with a contrast comparable to standard T1-weighted images were created by averaging across the echoes acquired in the sequence.

T2-weighted images of the whole brain were obtained using a 3D turbo spin echo sequence (repetition time = 3200 ms, echo time = 409 ms, matrix = 256x256, 176 sagittal slices with no gap, 1.0x1.0x1.0 mm^3^ isotropic voxels). FLAIR images of the whole brain were obtained using a 3D turbo inversion recovery sequence (repetition time = 5000 ms, echo time = 395 ms, inversion time = 1800 ms, matrix = 256x256, 176 sagittal slices with no gap, 1.0x1.0x1.0 mm^3^ isotropic voxels).

2.2. Image assessment {#s0020}
---------------------

All images were assessed by a consultant radiologist (C.G.M.) with experience in neuroradiology who was blinded to headache diagnoses and clinical data. To assess the burden of deep white matter hyperintensities (WMHs), we applied a slightly modified version of Scheltens' semiquantitative scale ( [@bib177], [@bib176]). Periventricular WMHs were assessed in three regions (frontal and posterior horns and bands) and rated as 0 (no periventricular WMH); 1 (pencil-thin lining); 2 (smooth halo or thick lining); or 3 (large confluent lesions). The three regional scores were summed up to a total score (range 0--9). In the present study of thalamic structure, data from subjects with significant deep white matter hyperintensities (Scheltens score 12 or more) or periventricular white matter hyperintensities (Scheltens score 6 or more) were excluded from further analyses.

2.3. MRI data analysis {#s0025}
----------------------

For pre-processing purposes, cortical reconstruction and volumetric segmentation was performed with the FreeSurfer image analysis suite v.6.0.0 (<http://surfer.nmr.mgh.harvard.edu>) using the standard *recon-all* pipeline. The technical details of these procedures are described in prior publications ([@b0020], [@b0040]). In short, reconstruction procedures comprised intensity-normalization to MNI-space, skull-stripping, filtering, segmentation and surface deformation. The quality of the skull-stripping and accuracy of the gray and white matter outer boundaries was reviewed by a trained researcher (S.H.N.) who was blinded to the grouping of the patients. In order to obtain volumetric data of ROIs we used specialised FreeSurfer tools for automated parcellation of gray and white matter ([@b0030]).

Thalamic nuclei were segmented using two complimentary approaches: 1) the *MAGeT Brain Algorithm* ([@b0010])*,* a multi-atlas segmentation (MAS) technique previously used in a multi-center migraine study ([@b0125]) and 2) a recently developed algorithm ([@b0110]), which relies on a probabilistic atlas derived from ex vivo MRI scans and histological specimens from six post mortem cases ([@b0110]).

### 2.3.1. Method 1: MAGeT brain algorithm {#s0030}

Thalamic nuclei were segmented using a multi-agent system (MAS) algorithm that relies on a collection of so-called atlases consisting of MRI scans and corresponding thalamus labelings. In brief, the MAS contains two steps: registration and label fusion. The registration step establishes a spatial correspondence between each atlas and a to-be-segmented target scan. Once a correspondence between each atlas MRI and the target MRI has been established, the labeling is warped to the target space. This procedure results in multiple candidate segmentations, as many as there are atlases, which are then fused into a consensus segmentation in the label fusion step. The technical details of this approach are described in prior publications ([@b0115]).

The MAGeT algorithm ([@b0010]) is based on a single atlas where the thalamus nuclei labelings were manually drawn on serial histological data. The thalamic nuclei included in the atlas are: Left and right lateral geniculate nucleus, medial geniculate nucleus, anterior nuclei, central nuclei, lateral dorsal, lateral posterior, medial dorsal, pulvinar, ventral anterior nucleus, ventral lateral nucleus and ventral posterior nucleus (see [Fig. 1](#f0005){ref-type="fig"}).Fig. 1MAGeT Brain Algorithm. This method implies multiple automatically generated registrations from a single histological atlas. Step 1 visualizes the initial step, registration, in the segmentation of the representative sample consisting of 31 subjects using the histological atlas Colin27. This process consists of 1.1) the estimation of a non-linear spatial transformation matching an input template to each subject and 1.2) applying that transformation to each set of labels. In step 2 the initially segmented set of subjects (representative sample) is 2.1) co-registered to each other using a leave-one-out technique and 2.2) the most frequently occurring voxels are chosen using voxelwise majority voting (label fusion). Step 3.1) comprises of the segmentation of the remaining subjects using the majority segmentations of the representative sample. Again, 3.2) the most frequently occurring voxels are chosen using voxelwise majority voting.

We applied our version of the MAGeT algorithm in the following way:1)A non-linear registration of the histological atlas to a subset of 31 subjects (see below) was applied using Advanced Normalization Tools. The initially segmented subset of subjects was representative with regard to the demographical and clinical features of the sample in order to capture the neuroanatomical variability of the sample. As there was only a single histological atlas, no label fusion was necessary at this step (see [Fig. 1](#f0005){ref-type="fig"}).2)Each subject in the representative sample was registered to the remaining subjects in the group (31 × 30 registrations) in a leave-one-out manner. This resulted in 30 candidate segmentations per subject, which were fused to a consensus segmentation using majority voting where the most frequently occurring label across the candidate labelings was assigned to each voxel (see [Fig. 1](#f0005){ref-type="fig"}). The initial segmentations of step 1 can be very noisy as they are based on a single atlas. Thus, we used the leave-one-out cross-registration step to obtain smoother segmentations.3)Finally, the rest of the subjects were segmented using the representative subset of subjects and corresponding segmentations. Each of the 31 atlases were registered to the remaining 255 scans (255 × 31 registrations) and the candidate segmentations in each subject were obtained using a voxel-wise majority vote. The segmentations were visually inspected to confirm that the outer border of the thalamus matched the intensity gradient in the MR scans by a trained researcher (S.H.N.). Thereby, specific attention was paid to the borders of the thalamus toward cerebrospinal fluid spaces and toward the surrounding white matter.

The representative sample consisted of 31 subjects, 16 healthy controls and 15 patients with migraine with aura. The representative sample, which was chosen from the whole group, was matched for age, disease distribution, number of lifetime aura attacks and number of aura attacks within the last 12 months in order to adequately capture the neuroanatomical variability of the sample. This number of subjects was found optimal to capture the population variability in previous work, and increasing the number did not increase the accuracy of the method ([@b0140])*.*

An overview of the thalamic nuclei included in the atlas is provided in [Fig. 2](#f0010){ref-type="fig"}.Fig. 2Representative example from a single subject of the location of thalamic nuclei obtained using segmentation Methods 1 (panel B) and 2 (panel C). Slice locations are shown in panel A, while names of individual nuclei and a colour code is provided in panel D.

### 2.3.2. Method 2: probabilistic atlas of the thalamic nuclei combining ex vivo MRI and histology {#s0035}

The thalamic nuclei were segmented using a fully automated segmentation method freely available as part of the FreeSurfer image analysis suite v.6.0.0. In brief, the segmentation problem is posed in terms of Bayesian inference where the task is to find the most probable thalamus nucleus labeling given the MRI scan of a target subject. The registration parameters, along with the parameters of a Gaussian mixture model (GMM) that models the distribution of intensities, are obtained as a maximum-a-posteriori estimate given the data. Subsequently, the segmentation is performed by assigning the most probable nucleus labels to each voxel given the MRI data, and registration and GMM parameters. Details on the segmentation approach can be found in previous publications ([@b0105], [@b0145]). An overview of the thalamic nuclei included in the atlas is provided in [Fig. 2](#f0010){ref-type="fig"}.

2.4. Statistical analyses {#s0040}
-------------------------

All analyses comparing volumes of regions of interest between groups were performed using R statistical software v3.5.2 and the \'nlme\' package v3.1.

We hypothesized a priori that, on a group level, thalamic nuclei volumes of both hemispheres would differ relative to corresponding volumes of controls. Theoretically, in the individual migraine patient, abnormal thalamic nuclei volumes could depend on the laterality of the perceived symptoms, e.g. patients predominantly experiencing right-sided pain or right-sided visual symptoms could have structural alterations of the left thalamus. However, clinical information relating to symptom laterality was not available in the present study. For these reasons, we compared left--right averages of thalamic volumes between groups rather than comparing left-sided and right-sided nuclei specifically

### 2.4.1. Individual-based analyses {#s0045}

The volumes of the thalamic nuclei (11 bilateral nuclei in Method 1 and 25 bilateral nuclei in Method 2) of patients were compared with the volume of the thalamic nuclei of controls in a linear mixed model with fixed effects covariates (age, educational level (low, medium, high), BMI, smoking, alcohol (units per week) and hypertension (blood pressure of \>160 systolic, or \>95 diastolic, or current use of antihypertensive drugs)) and random intercepts. The fixed covariates were included in the final model if significant at a probability level of less than 0.05 estimated by likelihood ratio testing (using forward stepwise selection). An interaction term between the subject category (i.e. patient or control) variable and the regions of interest (thalamic nuclei) was included to test if patients and controls differed in volume of the thalamic nuclei considering all differences at the remaining regions. The dependence of the different regions within individuals was captured by a random intercept. Since confounding due to any between-group differences in the volume of the whole thalamus would be avoided using this approach, we did not normalize the volumes of the thalamic nuclei to head size or intracranial volume. A separate intercept captured dependency of individuals where both twins in a pair were included (18 pairs where both twins had migraine with aura were included). Inference on the difference in volume and the corresponding 95% confidence intervals (CIs) were obtained for each location in the model using Wald tests of the relevant contrast, and a two-sided probability level of less than 0.05 was considered statistically significant. Within each of the two methods the results were corrected for testing of multiple thalamic nuclei using the Benjamini-Hochberg False Discovery Rate (FDR) approach set at an α level of 0.05.

Further, we investigated whether there was a relation between migraine aura frequency (categorical data of aura attacks during the last 12 months and lifetime number of aura attacks, respectively, see [Table 1](#t0005){ref-type="table"}) and the volumes of thalamic nuclei. This was done using two additional linear mixed models that were applied to the patient data specifically: one including an interaction term between aura attacks in the past 12 months and the thalamic nuclei volumes, and one including an interaction term between lifetime number of aura attacks and the thalamic nuclei volumes. These models included the same fixed effects covariates and intercepts as described above. We used likelihood ratio testing to determine if inclusion of the migraine aura frequency covariates provided a better fit compared to similar models without these covariates. Further, we created boxplots for each thalamic nucleus showing the volume distribution in the different migraine aura frequency groups (aura attacks during the last 12 months and lifetime number of aura attacks plotted separately, see [Supplementary Figs. 1--4](#s0110){ref-type="sec"}).Table 1Characteristics of study participants.Individual-based analysesWithin-pair analysesCharacteristicPatients with migraine with aura n = 156Controls n = 126*P* value[a](#tblfn1){ref-type="table-fn"}Patients with migraine with aura n = 29Co-twins n = 29*P* value[b](#tblfn2){ref-type="table-fn"}Age at time of MRI scan, years47.5 ± 6.447.4 ± 7.60.6949.4 ± 5.249.5 ± 5.20.33Zygosity -- no. (%) Monozygotic68 (43.6)50 (39.7)0.5314141.00 Dizygotic -- same sex57 (36.5)48 (38.1)0.8015151.00 Dizygotic -- opposite sex31 (19.9)28 (22.2)0.64NANANALow education level[c](#tblfn3){ref-type="table-fn"} -- no. (%)50 (32.1)32 (25.4)0.226 (20.7)9 (31.0)0.18Smoker, ever -- no. (%)79 (50.6)62 (49.2)0.7815 (51.7)14 (48.3)1.00Alcohol, drinks per week3.7 ± 5.24.8 ± 5.40.073.5 ± 2.93.7 ± 3.70.71BMI[d](#tblfn4){ref-type="table-fn"}24.8 ± 4.324.6 ± 4.30.7225.1 ± 4.024.5 ± 3.50.33Hypertension[e](#tblfn5){ref-type="table-fn"} -- no. (%)49 (31.4)26 (20.6)0.04812 (40.0)11 (36.7)0.75Scheltens scores[f](#tblfn6){ref-type="table-fn"} Periventricular white matter hyperintensities3 ± 22 ± 20.751 ± 12 ± 20.40 Deep white matter hyperintensities1 ± 31 ± 30.852 ± 42 ± 50.40Migraine with aura Age at onset, years23.0 (10.9)NA25.4 (10.6)NA Age at last attack[g](#tblfn7){ref-type="table-fn"}, years42.6 (9.7)NA41.5 (11.3)NA Aura attacks in last 12 months[g](#tblfn7){ref-type="table-fn"}^,^[h](#tblfn8){ref-type="table-fn"} -- no. (%)  057 (36.5)NA18 (62.1)NA  1--569 (44.2)NA9 (31.0)NA  \>529 (18.6)NA2 (6.9)NA Headache presence in relation to aura -- no. (%)  Always aura with headache97 (62.2)NA19 (65.5)NA  Aura with & without headache47 (30.1)NA9 (31.0)NA  Aura never with headache12 (7.7)NA1 (3.5)NA Aura type -- no. (%)  Visual154 (98.7)NA28 (96.6)NA  Sensory32 (20.5)NA3 (10.3)NA  Aphasia18 (11.5)NA4 (13.8)NA  Motor1 (0.6)NA1 (3.5)NA Lifetime no. of aura attacks -- no. (%)  2--935 (22.4)NA10 (34.5)NA  10--4947 (30.1)NA12 (41.4)NA  50--10031 (19.9)NA4 (13.8)NA  \>10043 (27.6)NA3 (10.3)NAMigraine without aura Ever[i](#tblfn9){ref-type="table-fn"} -- no. (%)33 (21.2)NA8 (27.6)10 (34.5)0.44 Lifetime no. of attacks -- no. (%)  5--497 (4.5)NA1 (3.5)5 (17.2)  50--1009 (5.8)NA5 (17.2)1 (3.5)  \>10017 (10.9)NA2 (6.9)4 (13.8)0.44 Last 12 months[g](#tblfn7){ref-type="table-fn"}, no. of attacks -- no. (%)  013 (8.3)NA5 (17.2)2 (6.9)  1--517 (10.9)NA2 (6.9)4 (13.8)  ≥68 (5.1)NA1 (3.5)4 (13.8)0.08 Days with tension-type headache in last 12 months[g](#tblfn7){ref-type="table-fn"} -- no. (%)  0--13112 (71.8)117 (92.9)25 (86.2)24 (82.8)  14--3026 (16.7)9 (7.1)3 (10.3)4 (13.8)  31--179[j](#tblfn100){ref-type="table-fn"}18 (11.5)00.331 (3.4)1 (3.5)0.71 Headache in 48 h before or 48 h after study scan[k](#tblfn10){ref-type="table-fn"} -- no. (%) Any type of headache29 (18.6)7 (5.6)0.515 (17.2)8 (27.6)0.35 Migraine[l](#tblfn11){ref-type="table-fn"}3 (1.9)0NA02 (6.9)NA[^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14]

### 2.4.2. Within-pair analyses {#s0050}

In the within-pair analysis, we investigated intrapair differences in mean volumes of the thalamic nuclei of twin pairs, where one of the twins had migraine with aura and the co-twin did not suffer from migraine with aura. This was done using paired t-tests, since this matched-pair analysis reduces the influence of several unmeasured confounders, and thus relies on the assumption of discordance in exposure and outcome. We abstained from within-pair analyses stratified by zygosity due to the small number of discordant twin pairs (14 monozygotic and 15 dizygotic pairs) that participated in the study. Results were corrected for testing of multiple thalamic nuclei using the Benjamini-Hochberg False Discovery Rate (FDR) approach set at an α level of 0.05.

3. Results {#s0055}
==========

A total of 172 migraine patients with aura, 34 co-twins and 139 controls were scanned. Due to imaging quality issues, 6 scans from patients, 4 scans from co-twins, and 2 scans from controls were excluded. In addition, 10 patients and 11 controls were excluded because they exceeded the a priori defined level of acceptable WMH burden. Thus, the results are based on data from 156 patients, 29 co-twins, and 126 controls. Patients were similar to controls with regard to age, and several lifestyle characteristics, although 31.4% of patients were classified as hypertensive, compared with 20.6% of controls (*P* = 0.048) ([Table 1](#t0005){ref-type="table"}). Headache characteristics of patients corresponded to our expectations based on previous population-based epidemiological studies of migraine with aura ([@b0035], [@b0155]).

3.1. Patients compared to controls {#s0060}
----------------------------------

The inclusion of the fixed effects covariates in the full model (age, educational level, BMI, smoking, alcohol, and hypertension) produced similar results, but a better fit than more parsimonious models (likelihood ratio testing *P* \< 0.05). This was the case for results from both Method 1 and Method 2.

According to the best fitted (i.e. full) model, we found no statistically significant volume differences of the thalamic nuclei using Method 1 or Method 2 after correction for multiple comparisons (see [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). Results corrected only for the effects of age are presented in [Supplementary Tables 1 and 2](#s0110){ref-type="sec"}.Table 2Results from Method 1. Volumes of thalamic nuclei in 156 women with migraine with aura compared with 126 migraine-free women. Values of volumes are in mm^3^ (SD).StructurePatients with migraine with auraControls*P* value[1](#tblfn12){ref-type="table-fn"}Anterior nuclei205.47 (29.99)209.08 (32.91)0.98Central nuclei421.19 (37.51)422.61 (43.18)0.98Lateral dorsal45.69 (11.58)47 (12.37)0.98Lateral geniculate nucleus310.16 (40.46)309.1 (45.76)0.98Lateral posterior648.99 (80.8)664.36 (94.38)0.98Medial dorsal1732.42 (190.04)1711.85 (180.64)0.98Medial geniculate nucleus301.33 (26.24)298.83 (32.61)0.98Pulvinar2996.72 (275.48)2956.33 (312.38)0.11Ventral anterior nucleus937.36 (114.15)951.57 (139.54)0.98Ventral lateral nucleus1375.38 (141.64)1397.63 (177.19)0.98Ventral posterior nucleus903.81 (82.62)908.02 (105.43)0.98[^15]Table 3Results from Method 2. Volumes of thalamic nuclei in 156 women with migraine with aura compared with 126 migraine-free women. Values of volumes are in mm^3^ (SD).StructurePatients with migraine with auraControls*P* value[1](#tblfn13){ref-type="table-fn"}Anteroventral259.51 (33.06)259.77 (32.09)0.96Central medial142.05 (18.49)141.82 (17.13)0.96Central lateral81.98 (12.86)79.91 (11.67)0.96Centromedian514.09 (48.51)509.21 (57.96)0.96Limitans suprageniculate54.08 (9.87)51.65 (9.84)0.96Laterodorsal63.54 (13.09)61.57 (12.81)0.96Lateral geniculate273.21 (52.63)269.14 (46.26)0.96Lateroposterior253.88 (27.47)253.5 (31.25)0.96Mediodorsal lateral parvocellular599.16 (76.02)591.85 (66.8)0.96Mediodorsal medial magnocellular1469.43 (177.27)1466.37 (146.37)0.96Medial geniculate211.08 (31.13)207.68 (27.27)0.96Medial ventral reuniens28.65 (4.07)28.19 (3.86)0.96Paracentral6.43 (0.93)6.54 (0.84)0.96Parafascicular123.19 (12.12)123.02 (14.61)0.96Paratential13.77 (1.36)13.62 (1.56)0.96Pulvinar anterior363.63 (47.93)357.21 (40.12)0.96Pulvinar inferior297.24 (43.7)293.81 (43.05)0.96Pulvinar lateral314.31 (45.15)311.19 (43.8)0.96Pulvinar medial1665.79 (180.88)1643.33 (175.53)0.96Ventral anterior756.31 (86.52)763.21 (83.5)0.96Ventral anterior magnocellular65.29 (7.06)65.5 (6.23)0.96Ventral lateral anterior1191.62 (128.84)1207.21 (139.05)0.96Ventral lateral posterior1574.31 (161.52)1587.56 (180.1)0.96Ventromedial38.93 (4.67)38.45 (4.79)0.96Ventral posterolateral1588.31 (172.94)1577.88 (180.24)0.96Whole thalamus11949.78 (1086.98)11909.18 (1053.51)0.96[^16]

Within the patient group we did not find any indications of the thalamic nuclei volumes being dependent on the number of migraine aura attacks during the past 12 months or lifetime number of aura attacks (see [Supplementary Figs. 1--4](#s0110){ref-type="sec"}).

3.2. Patients compared to co-twins {#s0065}
----------------------------------

The within-pair analyses showed no volume differences for any nuclei between patients and co-twins. This was the case for Method 1 and Method 2 (see [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}).Table 4Results from Method 1. Volumes of thalamic nuclei in 29 women with migraine with aura and their twin sisters with no history of migraine with aura. Values of volumes are in mm^3^ (SD).StructurePatientsControls*P* value[1](#tblfn14){ref-type="table-fn"}Anterior nuclei198.31 (28.2)195.79 (29.57)0.95Central nuclei418.00 (35.18)420.1 (40.53)0.95Lateral dorsal45.03 (10.06)42.41 (11.91)0.95Lateral geniculate nucleus298.52 (37.03)308.24 (38.83)0.95Lateral posterior654.07 (79.18)610.72 (76.14)0.44Medial dorsal1752.07 (190.31)1755.03 (185.97)0.95Medial geniculate nucleus309.83 (28.04)310.66 (26.12)0.95Pulvinar2978.83 (286.45)3026.52 (289.88)0.95Ventral anterior nucleus936.14 (134.28)913 (118.29)0.95Ventral lateral nucleus1396.76 (191.18)1370.14 (154.03)0.95Ventral posterior nucleus910.72 (109.97)902.55 (98.75)0.95[^17]Table 5Results from Method 2. Volumes of thalamic nuclei in 29 women with migraine with aura and their twin sisters with no history of migraine with aura. Values of volumes are in mm^3^ (SD).StructurePatientsControls*P* value[1](#tblfn15){ref-type="table-fn"}Anteroventral256.3 (41.12)257.1 (34.91)0.99Central medial142.05 (18.95)142.52 (22.09)0.99Central lateral81.31 (13.14)85.35 (14.85)0.99Centromedian513.14 (68.56)512.05 (49.82)0.99Limitans suprageniculate62.04 (13.46)68.01 (13.46)0.99Laterodorsal256.27 (44.25)259.63 (55.02)0.99Lateral geniculate246.08 (33.93)253.14 (33.11)0.99Lateroposterior54.37 (10.38)54.15 (9.01)0.99Mediodorsal lateral parvocellular597.72 (88.68)592.06 (75.18)0.99Mediodorsal medial magnocellular1489.23 (193.77)1469.5 (176.02)0.99Medial geniculate205.39 (28.78)207.5 (30.13)0.99Medial ventral reuniens28.71 (3.87)29.11 (5.05)0.99Paracentral6.4 (0.8)6.41 (0.85)0.99Parafascicular119.94 (14.16)122.17 (11.33)0.99Paratential13.76 (1.77)13.82 (1.5)0.99Pulvinar anterior354.37 (44.26)353.92 (40.72)0.99Pulvinar inferior280.98 (44.89)290.86 (38.9)0.99Pulvinar lateral307.44 (54.55)297.58 (40.43)0.99Pulvinar medial1635.42 (200.34)1659.4 (176.85)0.99Ventral anterior752.67 (103.67)751.7 (91.19)0.99Ventral anterior magnocellular64.73 (7.64)64.91 (6.85)0.99Ventral lateral anterior1181.05 (157.14)1174 (117.53)0.99Ventral lateral posterior1558.95 (206.5)1545.34 (147.58)0.99Ventromedial38.71 (5.52)38.25 (4.56)0.99Ventral posterolateral1574.9 (215.74)1554.61 (167.1)0.99Whole thalamus11821.93 (1365.34)11803.09 (1070.5)0.99[^18]

4. Discussion {#s0070}
=============

In this large, population-based study of a well-characterized sample of migraine patients with aura, compared to matched healthy controls and to aura-free co-twins, using two complementary, advanced analysis methods, we did not find any between-group differences of thalamic nuclei volumes. Further, we did not find a relation between migraine aura frequency and thalamic nuclei volumes in this dataset.

4.1. Previous studies of thalamic nuclei volumes in migraine {#s0075}
------------------------------------------------------------

A previous, multi-centre study of 131 migraine patients (38 with aura, mean age 30.8 years, 109 women, mean monthly attack frequency 3.2, mean disease duration 14 years) recruited from four international tertiary headache centres reported smaller volumes in patients of the central nuclear complex, anterior nucleus, and lateral dorsal nucleus, compared to 115 healthy volunteers. The study used 3D T1-weighted MR images acquired at 3 T and the MAGeT Brain Algorithm, corresponding to "Method 1" of the present study. The study found no between-group differences in separate analyses of controls vs. migraine patients without aura, controls vs. migraine patients with aura, and patients with aura vs. patients without aura. Another previous 3 T MRI study compared thalamic nuclei volumes of 35 migraine without aura patients (mean age 37.9 years, 26 women, mean monthly attack frequency 3.8, mean disease duration 9.2 years) from a single South Korean tertiary centre to those of 40 healthy volunteers using a probabilistic atlas-based approach identical to "Method 2" of the present study. This study reported larger volumes in the patient group of the medial geniculate and anteroventral nuclei and smaller volumes of the parafascicular nuclei. In summary, the two previous studies had the same objective of evaluating volumes of thalamic nuclei in migraine patients, used comparable input data, applied two different data analysis methods, and reached different conclusions. The most important differences between the two previous studies and the present study are that 1) we included only women and only migraine patients *with* aura, 2) patients of the present study had a markedly lower attack frequency, 3) patients of the previous studies were recruited from specialized headache centres and may not be comparable to migraine patients of the general population.

While our results indicate no abnormalities of thalamic volume in migraine patients with aura in general, we cannot rule out that such abnormalities might be present in migraine patients without aura specifically, or more severely affected migraine patients. Indeed, alteration of thalamic structure could be a consequence of repeated migraine headache attacks. A correlation between migraine attack frequency or disease duration and the volumes of thalamic nuclei would support the latter possibility. However, none of the two previous studies, or the present study, found such correlations.

4.2. Other studies of thalamic structure in migraine {#s0080}
----------------------------------------------------

A large (N = 918 total, 143 migraine patients) population-based study using surface-based morphometry to investigate subcortical grey matter structure volumes in headache sufferers, including migraine patients, found no abnormalities of the volume of thalamus related to migraine or other headache types ([@b0100]). In support, a clinic-based study comparing thalamic volume of 60 patients with migraine with aura (42 women, 18 men) to age and gender matched healthy controls, found no difference between groups ([@b0085]). Several studies have used voxel-based morphometry (VBM) to look for differences in grey matter volume between migraine patients and controls with inconsistent results ([@b0090]). Interestingly in this context, VBM abnormalities of the thalamus related to migraine have not been reported ([@b0095]).

A combination of different MRI contrasts, quantitative T1, magnetization transfer ratio (MTR), quantitative T2\*, and generalised fractional anisotropy, was used in a study to explore thalamic microstructure in migraine patients with and without aura ([@b0060]). The authors of this study reported shorter thalamic T1 relaxation time and higher MTR and T2\* relaxation time specifically in migraine *with* aura and speculated that these changes could represent increased iron deposition and myelin content/cellularity in the thalamus as a whole. The authors further concluded that these differences were not related to pain processing, since the ventral-postero-medial and ventral-postero-lateral nuclei were not specifically affected. Indeed, a recent fMRI study of pain processing in interictal migraine with aura did not find abnormal thalamic activation ([@b0160]).

4.3. Strengths and limitations of the present study {#s0085}
---------------------------------------------------

A main strength of the present study was the use of the population-based Danish Twin Registry, which enabled us to identify a large number of well-characterised patients and matched controls. Rather than studying a mixed migraine population (migraine without aura and migraine with aura patients), the present study specifically focused on a pure phenotype of migraine patients with aura. Also, we were able to perform paired analyses of twin pairs discordant for migraine with aura, an approach that strongly reduced or eliminated potential confounding effects of genes and common environment. The migraine diagnosis was established through telephone interviews with physicians based on internationally acknowledged criteria and all subjects were scanned using the same MRI scanner at a single centre. Some potential limitations also need to be considered. A subgroup (36.5%) of patients had not had a migraine attack in the previous year. Thus, we may have been unable to detect potential structural thalamic abnormalities related to frequent or recent migraine attacks. The paired analyses were based on 29 cases compared to 29 controls and thus probably only had power to detect relatively large differences in thalamic nuclei volume. We cannot rule out that small between-group differences would have been detectable in a larger sample size. Our results obtained in women do not generalise to male patients. Indeed, previous MRI studies showed differences in thalamic volume and thalamic microstructure between men and women ([@b0120], [@b0130]), although with conflicting results ([@b0150]). Due to the observational nature of this study, it we cannot rule out the possibility that unmeasured or insufficiently measured confounders may have influenced our results.

Based on the results of the present study, we cannot exclude potential microstructural abnormalities or abnormal thalamic function in migraine with aura.

In conclusion, our results indicate that female migraine patients with aura do not have abnormal volumes of thalamic nuclei.
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[^2]: Means ± standard deviation, unless otherwise specified.

[^3]: Patients versus controls. Generalized linear mixed models (binomial for proportions and Gaussian for means) were used to test the null hypothesis: there is no difference between patients and controls. Random intercepts for twin pairs were included to adjust for twin pair cluster effects.

[^4]: Patients versus co-twins. Generalized linear mixed models (binomial for proportions and Gaussian for means) were used to test the null hypothesis: there is no difference between patients and co-twins. Random intercepts for twin pairs were included to adjust for twin pair status.

[^5]: Education level was defined as low in women with less than 12 years of schooling and less than 3 years of vocational training.

[^6]: Body Mass Index, the weight in kg divided by the square of the height in meters.

[^7]: Hypertension was defined as systolic blood pressure of 160 mmHg or higher, or diastolic blood pressure of 95 mmHg or higher, or current use of antihypertensive drugs for hypertension.

[^8]: Values for Scheltens scores are medians ± interquartile range

[^9]: In 12 months before physician-conducted phone interview, establishing headache diagnoses according to International Headache Society classification criteria.

[^10]: Information missing for 1 patient.

[^11]: Per protocol, co-twins with migraine without aura could be included in the study.

[^12]: Potential controls with \> 30 tension-type headache days in 12 months prior to interview were excluded by design.

[^13]: Participants completed questionnaire information on headaches within last 48 h on the day they were scanned and were subsequently phone-interviewed by a physician 48--72 h after the scan to verify this information and to ascertain presence of headaches during or after the study scan.

[^14]: Paricipants reported exclusively migraine without aura attacks.

[^15]: *P* values are corrected for comparison of multiple nuclei using the Benjamini-Hochberg False Discovery Rate (FDR) approach.

[^16]: *P* values are corrected for comparison of multiple nuclei using the Benjamini-Hochberg False Discovery Rate (FDR) approach.

[^17]: *P* values are corrected for comparison of multiple nuclei using the Benjamini-Hochberg False Discovery Rate (FDR) approach.

[^18]: *P* values are corrected for comparison of multiple nuclei using the Benjamini-Hochberg False Discovery Rate (FDR) approach.
